Freenome’s Breakthrough and Alamar’s Automation Push the Next Phase of Multiomics
Regulatory wins and automated workflows are making multiomics practical for serial screening, neuro testing, and longitudinal care.
What is this trend?
FDA momentum and automated plasma workflows are turning multiomics from promising biomarker science into repeatable, clinically deployable testing for screening, neurodegeneration, and surveillance.
- FDA designations and clearances are validating blood-based diagnostics for real care pathways.
- Automation is the next moat: low-volume, high-throughput workflows enable serial testing at scale.
- Neuro biomarker panels are expanding from research tools into operational Alzheimer’s and cognitive decline use cases.
- Value is shifting toward longitudinal data, reimbursement, and workflow integration—not single-test performance.
- Platforms that combine analytics, automation, and regulatory progress are best positioned to win.
What’s the latest?
On August 12, the FDA granted Freenome’s SimpleScreen Lung Breakthrough Device Designation, while Zepto Life secured a major liquid biopsy grant, reinforcing that blood-based diagnostics are advancing
How it developed
- Infrastructure wins in diagnostics, AI embeds in workflows, and serial testing drives oncology revenue
- Serial Blood Testing Is Becoming the Economic Engine in Oncology
- Workflow-specific AI clears first, companion diagnostics gain reimbursed access, and multiomics shifts to deployment
- Freenome’s Breakthrough and Alamar’s Automation Push the Next Phase of Multiomics
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
If you sell into this industry
AI-Powered Liquid Biopsy Emerges as a High-Stakes Frontier in Precision Oncology, Attracting Hundreds of Millions in Venture and Public Funding
News analysis of AI-powered multiomics liquid biopsy funding and tech advances shaping precision oncology.
Yahoo Finance · News
Read →BCC Research Highlights Investment Surge in AI-Powered Liquid Biopsy
Analysis of AI-powered liquid biopsy funding, linking multiomics advances to major venture and public investment.
citybiz · News
Read →
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Research publication with interviews on Capture-Seq™ ctDNA purity, enabling serial MCED/MRD as oncology’s economic engine.
PR Newswire - Consumer Technology · News
Read →